y 27632 has been researched along with gallic acid in 3 studies
| Studies (y 27632) | Trials (y 27632) | Recent Studies (post-2010) (y 27632) | Studies (gallic acid) | Trials (gallic acid) | Recent Studies (post-2010) (gallic acid) |
|---|---|---|---|---|---|
| 1,924 | 3 | 891 | 4,793 | 42 | 2,579 |
| Protein | Taxonomy | y 27632 (IC50) | gallic acid (IC50) |
|---|---|---|---|
| Urokinase-type plasminogen activator | Homo sapiens (human) | 6.6 | |
| Tissue-type plasminogen activator | Homo sapiens (human) | 6.6 | |
| Plasminogen activator inhibitor 1 | Homo sapiens (human) | 6.6 | |
| Urokinase-type plasminogen activator | Mus musculus (house mouse) | 6.6 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 4.03 | |
| Matrilysin | Homo sapiens (human) | 4.03 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 4.65 | |
| Alpha-synuclein | Homo sapiens (human) | 4.43 | |
| 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 | Homo sapiens (human) | 4.03 | |
| Polypeptide N-acetylgalactosaminyltransferase 2 | Homo sapiens (human) | 1.37 | |
| Alpha-(1,3)-fucosyltransferase 7 | Homo sapiens (human) | 4.03 | |
| CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 | Homo sapiens (human) | 4.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, J; Parekh, N | 1 |
| Hashimoto, T; Honda, K; Momose, K; Ohata, H | 1 |
| Feng, CH; Hsieh, SC; Hsu, SL; Wu, CC; Yen, JH | 1 |
3 other study(ies) available for y 27632 and gallic acid
| Article | Year |
|---|---|
Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Amides; Angiotensin II; Animals; Arginine Vasopressin; Blood Pressure; Calcium Channel Blockers; Enzyme Inhibitors; Female; Gallic Acid; Indoles; Nifedipine; Norepinephrine; Pyridines; Rats; Rats, Wistar; Renal Circulation; Signal Transduction; Staurosporine; Vasoconstrictor Agents | 2003 |
Lysophosphatidic acid induces histamine release from mast cells and skin fragments.
Topics: Amides; Animals; Calcimycin; Calcium; Calcium Channel Blockers; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gallic Acid; Histamine Release; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Ionophores; Lysophospholipids; Male; Mast Cells; Mice; Mice, Inbred ICR; Peritoneum; Protein Serine-Threonine Kinases; Pyridines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Skin; Species Specificity; Time Factors | 2005 |
Gallic acid attenuates TGF-β1-stimulated collagen gel contraction via suppression of RhoA/Rho-kinase pathway in hypertrophic scar fibroblasts.
Topics: Amides; Cicatrix, Hypertrophic; Collagen; Fibroblasts; Gallic Acid; Humans; Myosin Light Chains; Phosphorylation; Pyridines; rhoA GTP-Binding Protein; Transforming Growth Factor beta1 | 2016 |